Of these alterations, ADP-ribosylation factor-like 6 (ARL6), transcript variant 1 is known to mediate the protein conducting channel Sec61β, and downregulation of this channel has been shown to increase resistance to known chemotherapeutic agents in ovarian cancer cells [59]. Here, ARL6 is linked to ovarian cancer.